Decompensated Cirrhosis
FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis
The FDA granted fast track designation to Lipocine’s LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for the treatment of sarcopenia in patients with decompensated cirrhosis, according to the manufacturer.
Mean arterial pressure target of 75 mmHg may boost survival in cirrhosis with septic shock
SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute kidney injury nonrecovery, in decompensated cirrhosis with septic shock, according to data.
VIDEO: Palliative care referrals critical in end-stage liver disease
PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, speaks with Healio about the underutilization of palliative care for patients with end-stage liver disease.
Patients with cirrhosis have higher risk for bleeding after endoscopic mucosal resection
PHILADELPHIA — Patients with cirrhosis had an increased risk for bleeding within 30 days of colorectal endoscopic mucosal resection compared with controls, although the need for reintervention or ICU admission was similar between groups.
FDA advisory panel votes against Ocaliva for PBC citing ‘concern for real possible harm’
An FDA advisory committee voted against approval for obeticholic acid in primary biliary cholangitis without cirrhosis or compensated cirrhosis with portal hypertension, citing “concern for real possible harm”.
Even with HCV cure, surveillance for portal hypertension, HCC ‘should be mandatory’
Despite achieving cure with direct-acting antivirals, patients with chronic hepatitis C virus-related decompensated cirrhosis remain at risk for progression of portal hypertension, further decompensation and hepatocellular carcinoma.
FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis
Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.
FDA approves Ipsen’s Iqirvo ‘to address unmet need’ in primary biliary cholangitis
The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.
Use of beta-blockers linked to acute kidney injury, mortality in decompensated cirrhosis
Use of nonselective beta-blockers was associated with stage 2 acute kidney injury and all-cause mortality among patients with decompensated cirrhosis waitlisted for liver transplantation, data showed.
FDA grants orphan drug designation to Ocelot Bio’s therapeutic peptide for ascites
The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor agonist-antagonist peptide for the treatment of ascites resulting from all causes except cancer, according to a company release.